Read More

Compass cuts 30% of staff as late-stage psilocybin drug trials face new delays

Compass Pathways (NASDAQ: CMPS) plans to cut about 30% of its workforce and halt early-stage research programs as the firm focuses resources on completing late-stage trials of its lead COMP360 program. The London-based company announced the restructuring alongside third-quarter financial results that showed a widening net loss of $38.5 million …

Read More

Massachusetts cannabis regulators approve new industry rules

On Wednesday, the Massachusetts Cannabis Control Commission gave unanimous approval to a new set of marijuana industry rules aimed at further expanding the trade across the state. Specifically, the new rules touch on protocols for home marijuana delivery, product transportation for testing purposes, expanding microbusiness and craft cooperatives, and increasing …